• Silexion entered definitive agreements for immediate exercise of Series E warrants for 3,216,928 ordinary shares at $0.2603.
• Gross proceeds expected at $837,366.36; closing set for about Sept. 29, 2026.
• In exchange, it will issue unregistered Series F warrants for 3,216,928 shares, expiring five years after key effectiveness dates.
• Unregistered Series G warrants for 3,216,928 shares also to be issued; expiry set at 24 months after the same triggers.
• Exercise price cut to $0.2603 for all outstanding Series E warrants covering 3,846,161 ordinary shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290803PRIMZONEFULLFEED1001275198) on September 29, 2026, and is solely responsible for the information contained therein.